AR127635A1 - MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF - Google Patents

MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF

Info

Publication number
AR127635A1
AR127635A1 ARP220103093A ARP220103093A AR127635A1 AR 127635 A1 AR127635 A1 AR 127635A1 AR P220103093 A ARP220103093 A AR P220103093A AR P220103093 A ARP220103093 A AR P220103093A AR 127635 A1 AR127635 A1 AR 127635A1
Authority
AR
Argentina
Prior art keywords
antigen
binding fragment
specifically binds
monoclonal antibody
disorders
Prior art date
Application number
ARP220103093A
Other languages
Spanish (es)
Inventor
Alina Valerevna Beliasnikova
Olga Leonidovna Kytmanova
Darya Olegovna Chernyshova
Mariia Aleksandrovna Shchemeleva
Anastasilia Isaevna Afremova
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021132869A external-priority patent/RU2808563C2/en
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR127635A1 publication Critical patent/AR127635A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a la IL-4Ra (subunidad a del receptor de interleucina-4). La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por IL-4Ra, usos de los anticuerpos o composiciones farmacéuticas de los mismos para tratar enfermedades o trastornos mediados por IL-4Ra, y usos de los anticuerpos y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por IL-4Ra.The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to IL-4Ra (a subunit of the interleukin-4 receptor). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing them, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody according to the invention, pharmaceutical compositions comprising the antibody according to the invention and other therapeutically active compounds, methods of treating IL-4Ra mediated diseases or disorders, uses of the antibodies or pharmaceutical compositions thereof to treat IL-4Ra mediated diseases or disorders, and uses of the antibodies and other compounds therapeutically active to treat diseases or disorders mediated by IL-4Ra.

ARP220103093A 2021-11-11 2022-11-10 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF AR127635A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021132869A RU2808563C2 (en) 2021-11-11 MONOCLONAL ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT WHICH SPECIFICALLY BINDS TO 4Rα (GD2 GANGLIOSIDE) AND ITS USE

Publications (1)

Publication Number Publication Date
AR127635A1 true AR127635A1 (en) 2024-02-14

Family

ID=86336553

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103093A AR127635A1 (en) 2021-11-11 2022-11-10 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF

Country Status (2)

Country Link
AR (1) AR127635A1 (en)
WO (1) WO2023085978A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292665B1 (en) * 2000-05-26 2015-07-08 Immunex Corporation Use of interleukin-4 antibodies and compositions thereof
ATE548388T1 (en) * 2003-11-07 2012-03-15 Immunex Corp ANTIBODIES BINDING TO THE INTERLEUKIN-4 RECEPTOR
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2758092C1 (en) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. ANTIBODY TO IL-4Rα AND APPLICATION THEREOF

Also Published As

Publication number Publication date
WO2023085978A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
CL2020000452A1 (en) B7-h4 antibodies and methods of using them.
RU2018139811A (en) MULTI-SPECIFIC ANTI-BINDING CONSTRUCTIONS TARGETING IMMUNOTHERAPEUTIC MEANS
PE20211284A1 (en) ANTI-NKG2A ANTIBODIES AND USES OF THEM
PE20221580A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
PE20200384A1 (en) METHOD OF MANUFACTURE OF BISPECIFIC ANTIBODIES, BISPECIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
AR053608A1 (en) ANTI-GM-CSF ANTIBODIES AND USES OF THE SAME
PE20190440A1 (en) ALPHA-SINUCLEIN ANTIBODIES AND USES OF THE SAME
CL2008003037A1 (en) Antibody that specifically binds il-4; nucleic acid molecules, host cells; pharmaceutical composition comprising said antibody; use of the antibody to treat cancer, among other diseases.
PE20180249A1 (en) NEUTRALIZING ANTIBODIES ANTI-CCL20
PE20191079A1 (en) IMMUNOGLOBULINS AND USES OF THEM
CO2023007172A2 (en) Interleukin-23 Receptor Peptide Inhibitors Compositions
PE20220489A1 (en) NATRIURETIC PEPTIDE 1 RECEPTOR ANTIBODIES AND METHODS OF USE
EA202192907A1 (en) MONOCLONAL ANTIBODY THAT SPECIFICLY BINDS TO GITR
CL2020001726A1 (en) Monoclonal antibodies and methods of using them.
PE20230464A1 (en) BINDING OF MULTI-SPECIFIC ANTIBODIES TO BCMA
CO2021008204A2 (en) Monoclonal Antibodies That Bind Specifically to the Trbv-9 Family Beta Region of the Human T-Cell Receptor, and Methods for Their Use
Choi et al. Displaying and delivering viral membrane antigens via WW domain–activated extracellular vesicles
AR127635A1 (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THAT SPECIFICALLY BINDS IL-4Ra, AND USE THEREOF
CO2021009689A2 (en) Monoclonal antibodies that specifically bind to the beta region of the trbv-9 family of the human T cell receptor, and methods for their use.
BR112022004941A2 (en) METHODS TO TREAT AUTOIMMUNE DISEASES WITH THE USE OF INTERLEUKIN-17 (IL-17) ANTAGONISTS
BR112022020716A2 (en) ANTI-TUMOR ANTIBODIES ASSOCIATED WITH ANTIGEN AND THEIR USES
ECSP23072412A (en) MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF THAT BINDS SPECIFICALLY TO GD2 (GANGLIOSIDE GD2), AND USE THEREOF
ECSP23097121A (en) Isolated bispecific antibody that specifically binds CD47 and PD-L1
BR112018070452A2 (en) a hutnfr1 receptor inhibitor, a pharmaceutical preparation comprising said inhibitor, a method of producing said inhibitor, use of said inhibitor in the manufacture of a product for treatment of a human individual, an isolated nucleic acid encoding said inhibitor, vector expression and host cells comprising said nucleic acid
Gao et al. A novel monospecific tetravalent IgG1-(scFv) 2 version shown enhanced neutralizing and Fc-mediated effector functions against SARS-CoV-2